[HTML][HTML] Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma
…, JP Quigley, RHP Law, JC Whisstock, AD Riddell… - Theranostics, 2020 - ncbi.nlm.nih.gov
Background: CUB domain-containing protein 1 (CDCP1) is a cell surface receptor regulating
key signalling pathways in malignant cells. CDCP1 has been proposed as a molecular …
key signalling pathways in malignant cells. CDCP1 has been proposed as a molecular …
[HTML][HTML] Patient and pathological predictors of management strategy for malignant polyps following polypectomy: a systematic review and meta-analysis
Purpose Malignant polyps present a treatment dilemma for clinicians and patients. This meta-analysis
sought to identify the factors that predicted the management strategy for patients …
sought to identify the factors that predicted the management strategy for patients …
[HTML][HTML] Development of 3D printed biodegradable mesh with antimicrobial properties for pelvic organ prolapse
To address the increasing demand for safe and effective treatment options for pelvic organ
prolapse (POP) due to the worldwide ban of the traditional polypropylene meshes, this study …
prolapse (POP) due to the worldwide ban of the traditional polypropylene meshes, this study …
PET imaging quantifying 68Ga-PSMA-11 uptake in metastatic colorectal cancer
TJ Cuda, AD Riddell, C Liu, VL Whitehall… - Journal of Nuclear …, 2020 - Soc Nuclear Med
At diagnosis, 22% of colorectal cancer (CRC) patients have metastases, and 50% later
develop metastasis. Peptide receptor radionuclide therapy (PRRT), such as 177 Lu-PSMA-617, …
develop metastasis. Peptide receptor radionuclide therapy (PRRT), such as 177 Lu-PSMA-617, …
Management of high and low risk malignant polyps: a population‐wide analysis
Aim The management of malignant polyps is a treatment dilemma in selecting between
polypectomy and colorectal resection. To assist clinicians, guidelines have been developed by …
polypectomy and colorectal resection. To assist clinicians, guidelines have been developed by …
In comparison with polypectomy, colorectal resection is associated with improved survival for patients diagnosed with malignant polyps
Aim Patients diagnosed with a malignant polyp generally have favourable overall survival (OS)
and cancer‐specific survival (CSS). However, it is unclear how choice in management for …
and cancer‐specific survival (CSS). However, it is unclear how choice in management for …
Missing parameters in malignant polyp histology reports: can appropriate decisions be made?
The treatment of colorectal malignant polyps is dependent upon quality reporting of the
histopathological features known to predict the risk of residual disease or lymph node metastasis. …
histopathological features known to predict the risk of residual disease or lymph node metastasis. …
[HTML][HTML] Preclinical molecular PET-CT imaging targeting CDCP1 in colorectal cancer
Colorectal cancer (CRC) is the third most common malignancy in the world, with 22% of
patients presenting with metastatic disease and a further 50% destined to develop metastasis. …
patients presenting with metastatic disease and a further 50% destined to develop metastasis. …
Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study
Background The interaction of the gut microbiota with the human host is implicated in the
pathogenesis of inflammatory and immunological diseases including ulcerative colitis (UC). …
pathogenesis of inflammatory and immunological diseases including ulcerative colitis (UC). …
Timing of surveillance colonoscopy following malignant colorectal polypectomy in Queensland
Introduction The management of malignant polyps presents a treatment challenge between
a colorectal resection and polypectomy alone. Patients managed with polypectomy alone …
a colorectal resection and polypectomy alone. Patients managed with polypectomy alone …